Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma.

Sara BadodiNicola PomellaYau Mun LimSebastian BrandnerGillian MorrisonSteven M PollardXinyu ZhangNicolae Radu Zabet Silvia Marino

Published in: Neuro-oncology (2022)

The molecular dissection of the CHD7-BMI1-MAPK regulatory axis in BMI1High;CHD7Low MB identifies this signature as a proxy to predict MAPK functional activation, which can be effectively drugged in preclinical models, and paves the way for further exploration of combined BMI1 and MAPK targeting in G4 MB patients.

Keyphrases

signaling pathway
pi k akt
body mass index
oxidative stress
weight gain
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
cell proliferation
prognostic factors
transcription factor
gene expression
cell therapy
single molecule
patient reported